9 years of historical data (2017–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Beam Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.9B | $2.7B | $2.0B | $2.1B | $2.7B | $5.1B | $3.8B | — | — | — |
| Enterprise Value | $2.8B | $2.6B | $1.9B | $1.8B | $2.7B | $4.7B | $3.8B | — | — | — |
| P/E Ratio → | -35.14 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 20.72 | 19.62 | 32.14 | 5.56 | 44.95 | 98.73 | 158970.84 | — | — | — |
| P/B Ratio | 2.27 | 2.21 | 2.78 | 2.14 | 3.73 | 6.19 | 15.54 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 121.56 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 18.61 | 30.24 | 4.86 | 44.07 | 90.77 | 156698.88 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Beam Therapeutics Inc. earns an operating margin of -274.6%. Operating margins have compressed from -46.7% to -274.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -8.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.0% | 84.0% | -478.7% | 100.0% | -411.5% | -347.8% | -429812.5% | -303338.9% | — | — |
| Operating Margin | -274.6% | -274.6% | -654.3% | -46.7% | -555.6% | -757.0% | -553166.7% | -417522.2% | — | — |
| Net Profit Margin | -57.2% | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% | -435144.4% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.1% | -8.1% | -43.9% | -15.5% | -37.1% | -69.1% | -112.3% | -66.7% | -177.5% | — |
| ROA | -6.2% | -6.2% | -29.4% | -9.5% | -20.5% | -38.5% | -64.0% | -48.5% | -136.1% | -363.4% |
| ROIC | -33.6% | -33.6% | -46.8% | -18.9% | -46.4% | -97.2% | -69.6% | -136.6% | — | — |
| ROCE | -33.3% | -33.3% | -38.2% | -14.9% | -28.5% | -48.7% | -55.7% | -56.0% | -66.6% | — |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $295M exceeds total debt of $154M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.22 | 0.18 | 0.24 | 0.18 | 0.44 | 0.31 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.11 | -0.16 | -0.27 | -0.07 | -0.50 | -0.22 | -0.06 | -1.09 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.77 | -8.77 | — | — | — | — | — | -401.89 | — | — |
Net cash position: cash ($295M) exceeds total debt ($154M)
Short-term solvency ratios and asset-utilisation metrics
Beam Therapeutics Inc.'s current ratio of 13.09x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.89x to 13.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.09 | 13.09 | 4.82 | 5.89 | 4.89 | 5.96 | 3.01 | 3.24 | 5.79 | 0.31 |
| Quick Ratio | 13.09 | 13.09 | 4.82 | 5.89 | 4.89 | 5.96 | 3.01 | 3.24 | 5.79 | 0.31 |
| Cash Ratio | 12.85 | 12.85 | 4.67 | 5.79 | 4.82 | 4.52 | 2.93 | 3.15 | 5.72 | 0.29 |
| Asset Turnover | — | 0.09 | 0.06 | 0.26 | 0.05 | 0.04 | 0.00 | 0.00 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 2112.11 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Beam Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $99M | $82M | $77M | $70M | $64M | $47M | $51M | $35M | $13M |
Compare BEAM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BEAMYou | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| PRME | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BEAM stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonBeam Therapeutics Inc.'s current P/E ratio is -35.1x. This places it at the 50th percentile of its historical range.
Beam Therapeutics Inc.'s return on equity (ROE) is -8.1%. The historical average is -66.3%.
Based on historical data, Beam Therapeutics Inc. is trading at a P/E of -35.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Beam Therapeutics Inc. has 84.0% gross margin and -274.6% operating margin.